Botulinum Toxin Type A for the Treatment of Urinary Tract Dysfunction in Neurological Disorders

O’Leary, Margie; Dierich, Mary

doi:10.7257/1053-816x.2010.30.4.229

Cited by 6 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among patients with chronic‐degenerative diseases, specifically neurogenic bladder patients as discussed in this study, the evolution of specific treatments has significantly increased life expectancy and conditions. Neurogenic bladder patients can be defined as patients affected by any nerve injury that interferes in the neurological bladder functioning due to a disease, lesion, or congenital defect that affect the brain, the spinal cord, or the nerves leading to the bladder, sphincter, or both (O'Leary & Dierich, ).…”

Section: Introductionmentioning

confidence: 99%

Quality of Life of Intermittent Urinary Catheterization Users and Their Caregivers: A Scoping Review

Fumincelli

Mazzo²,

Martins

et al. 2017

Worldviews Ev Based Nurs

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Quality of Life of Intermittent Urinary Catheterization Users and Their Caregivers: A Scoping Review

Fumincelli

Mazzo²,

Martins

et al. 2017

Worldviews Ev Based Nurs

View full text Add to dashboard Cite

show abstract

“…Stoppers on needles tend to prevent the risk of perforation. Needles are typically 22 to 27‐gauge and equal to 4 mm in length .…”

Section: Resultsmentioning

confidence: 99%

“…Stoppers on needles tend to prevent the risk of perforation. Needles are typically 22 to 27-gauge and equal to 4 mm in length (35). The currently available needles for onabotA injection used by the physicians surveyed are summarised in Table 6, in the order of preference and rationale provided by the physicians.…”

Section: Needle Selectionmentioning

confidence: 99%

Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In PD, the bladder hyperactivity mechanism may result from removal of the inhibitory mechanism of dopamine exertion via the pars compacta of the substantia nigra mediated by D1 receptors (through the inability to activate D1 mediated tonic inhibition) on the urinary reflex . It seems that the other mechanisms may include preferential damage to the inhibitory dopaminergic neurons …”

Section: Introductionmentioning

confidence: 99%

“…NGB often has a significant impact on quality of life with limitation of activities, and incontinence has an additional negative impact on quality of life because of embarrassment, depression, and social isolation . Without treatment, NGB leads to sepsis and renal failure that imposes the high burden on each health care system of communities …”

Section: Introductionmentioning

confidence: 99%

Management of neurogenic bladder in patients with Parkinson's disease: A systematic review

Hajebrahimi

Chapple

Pashazadeh

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims:To assess the different treatment methods in management of neurogenic bladder (NGB) in patients with Parkinson's disease (PD). Methods: A systematic search was performed in Cochrane library, EMBASE, Proquest, Clinicaltrial.gov, WHO, Google Scholar, MEDLINE via PubMed, Ovid, ongoing trials registers, and conference proceedings in November 11, 2017. All randomized controlled trials (RCTs) or quasi-RCTs comparing any treatment method for management of NGB in patients with PD were included. The titles and abstracts of all identified studies were evaluated independently by two investigators. Once all of the potential related articles were retrieved, each author separately evaluated the full text of each article and the quality of the methodology of the selected studies using the Cochrane appraisal risk of bias checklist and then the data about the patient's outcomes was extracted. We registered the title in Joanna Briggs Institute (JBI) that is available in http://joannabriggs.org/research/registered_titles.aspx. Results: We included 41 RCTs or quasi-RCTs or three observational study with a total of 1063 patients that evaluated pharmacological, neurosurgical, botulinum toxin, electrical neuromodulation, and behavioral therapy effects on NGB. Among the included studies only solifenacin succinate double-blind, randomized, placebocontrolled study was assessed as low risk of bias, and treatment led to an improvement in urinary incontinence. Conclusions: Although several interventions are available for treatment NGB in patients with PD, at present there is little or no evidence that treatment improves patient outcomes in this population. Additional large, well designed, randomized studies with improved methodology and reporting focused on patient-centered outcomes are needed.

show abstract

Botulinum Toxin Type A for the Treatment of Urinary Tract Dysfunction in Neurological Disorders

Cited by 6 publications

References 0 publications

Quality of Life of Intermittent Urinary Catheterization Users and Their Caregivers: A Scoping Review

Quality of Life of Intermittent Urinary Catheterization Users and Their Caregivers: A Scoping Review

Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure

Management of neurogenic bladder in patients with Parkinson's disease: A systematic review

Contact Info

Product

Resources

About